University of Cologne: Hodgkin Disease trials
The registry lists 30 Hodgkin Disease studies with University of Cologne as lead sponsor. 5 are open to participants now and 1 have results posted.
Phase 1 3Phase 2 21Phase 3 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06919679Phase 2
- Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin LymphomaNot yet recruitingNCT06916416Phase 2
- Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
- Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT04838652Phase 2
- Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin LymphomaRecruitingNCT04837859Phase 2
- Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem CellsCompletedNCT00398411Phase 3Results posted
- Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 TherapyActive, not recruitingNCT03480334Phase 2
- Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
- GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02321592Phase 2
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
- Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaCompletedNCT01569204Phase 2
- Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01453504Phase 1/2
- HD17 for Intermediate Stage Hodgkin LymphomaCompletedNCT01356680Phase 3
- Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell TransplantationCompletedNCT01283776Phase 2
- Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)CompletedNCT01187303Phase 2
- Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma PatientsCompletedNCT01056679Phase 1
- Protection of Ovarian Function in Female Patients With Hodgkin LymphomaCompletedNCT01014507Phase 2
- HD16 for Early Stage Hodgkin LymphomaStatus unknownNCT00736320Phase 3
- HD18 for Advanced Stages in Hodgkins LymphomaCompletedNCT00515554Phase 3
- PVAG-14 Pilot for Intermediate Stages Hodgkin LymphomaTerminatedNCT00512980Phase 2
- Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)CompletedNCT00346684Phase 2
- Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins LymphomaCompletedNCT00284271Phase 2
- HD12 for Advanced StagesCompletedNCT00265031Phase 3
- HD10 for Early StagesCompletedNCT00265018Phase 3
- HD11 for Intermediate StagesCompletedNCT00264953Phase 3
- Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's LymphomaTerminatedNCT00148018Phase 2
- Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's LymphomaCompletedNCT00147875Phase 1/2